Serological responses in humans to the smallpox vaccine LC16m8

Journal of General Virology

Volumn 92, Issue 10, 2011, Pages 2405-2410

  Johnson, Benjamin F ^a   Kanatani, Yasuhiro ^b   Fujii, Tatsuya ^c   Saito, Tomoya ^d   Yokote, Hiroyuki ^e   Smith, Geoffrey L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c Central Hospital   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VIRUS PROTEIN;

ANTIBODY RESPONSE; ARTICLE; BIOLOGICAL WARFARE; HUMAN; JAPANESE; PRIORITY JOURNAL; REVACCINATION; SMALLPOX; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HUMANS; SMALLPOX; SMALLPOX VACCINE; VIRAL PROTEINS;

ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 80052917756     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.034207-0     Document Type: Article

References (35)

1. Aguado, B., Selmes, I. P. & Smith, G. L. (1992). Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus. J Gen Virol 73, 2887-2902.
2. Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D. & Isaacs, S. N. (2004). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325, 425-431.
3. Benhnia, M. R., McCausland, M. M., Moyron, J., Laudenslager, J., Granger, S., Rickert, S., Koriazova, L., Kubo, R., Kato, S. & Crotty, S. (2009). Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 83, 1201-1215.
4. Boulter, E. A. & Appleyard, G. (1973). Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol 16, 86-108.
5. Davies, D. H., McCausland, M. M., Valdez, C., Huynh, D., Hernandez, J. E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P. L. & Crotty, S. (2005). Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79, 11724-11733.
6. Davies, D. H., Molina, D. M., Wrammert, J., Miller, J., Hirst, S., Mu, Y., Pablo, J., Unal, B., Nakajima-Sasaki, R. & other authors (2007). Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7, 1678-1686.
7. Earl, P. L., Americo, J. L., Wyatt, L. S., Eller, L. A., Whitbeck, J. C., Cohen, G. H., Eisenberg, R. J., Hartmann, C. J., Jackson, D. L. & other authors (2004). Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182-185.
8. Empig, C., Kenner, J. R., Perret-Gentil, M., Youree, B. E., Bell, E., Chen, A., Gurwith, M., Higgins, K., Lock, M. & Rice, A. (2006). Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 24, 3686-3694.
9. Engelstad, M. & Smith, G. L. (1993). The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194, 627-637.
10. Engelstad, M., Howard, S. T. & Smith, G. L. (1992). A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801-810.
11. Esposito, J. J., Sammons, S. A., Frace, A. M., Osborne, J. D., Olsen- Rasmussen, M., Zhang, M., Govil, D., Damon, I. K., Kline, R. & other authors (2006). Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science 313, 807-812.
12. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organisation.
13. Gordon, S. N., Cecchinato, V., Andresen, V., Heraud, J. M., Hryniewicz, A., Parks, R. W., Venzon, D., Chung, H. K., Karpova, T. & other authors (2011). Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 203, 1043-1053.
14. Hashizume, S., Yoshizawa, H., Morita, M. & Suzuki, K. (1985). Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In Vaccinia Viruses as Vectors for Vaccine Antigens, pp. 87-99. Edited by G. V. Quinnan. New York: Elsevier Science Publishing Co.
15. Isaacs, S. N., Wolffe, E. J., Payne, L. G. & Moss, B. (1992). Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol 66, 7217-7224.
16. Kenner, J., Cameron, F., Empig, C., Jobes, D. V. & Gurwith, M. (2006). LC16m8: an attenuated smallpox vaccine. Vaccine 24, 7009-7022.
17. Kidokoro, M., Tashiro, M. & Shida, H. (2005). Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A 102, 4152-4157.
18. Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968-National surveillance in the United States. N Engl J Med 281, 1201-1208.
19. Law, M., Pütz, M. M. & Smith, G. L. (2005). An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 86, 991-1000.
20. Massung, R.F., Liu, L. I., Qi, J., Knight, J.C., Yuran, T.E., Kerlavage, A. R., Parsons, J. M., Venter, J. C. & Esposito, J. J. (1994). Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201, 215-240.
21. Meseda, C. A., Mayer, A. E., Kumar, A., Garcia, A. D., Campbell, J., Listrani, P., Manischewitz, J., King, L. R., Golding, H. & other authors (2009). Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model. Clin Vaccine Immunol 16, 1261-1271.
22. Midgley, C. M., Putz, M. M., Weber, J. N. & Smith, G. L. (2008). Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol 89, 2992-2997.
23. Moss, B. (2011). Smallpox vaccines: targets of protective immunity. Immunol Rev 239, 8-26.
24. Parrino, J., McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T. &other authors (2007). Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-nai{dotless}̈ve and vaccinia-immune individuals. Vaccine 25, 1513-1525.
25. Pütz, M. M., Alberini, I., Midgley, C. M., Manini, I., Montomoli, E. & Smith, G. L. (2005). Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 86, 2955-2960.
26. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315.
27. Roberts, K. L. & Smith, G. L. (2008). Vaccinia virus morphogenesis and dissemination. Trends Microbiol 16, 472-479.
28. Saijo, M., Ami, Y., Suzaki, Y., Nagata, N., Iwata, N., Hasegawa, H., Ogata, M., Fukushi, S., Mizutani, T. & other authors (2006). LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol 80, 5179-5188.
29. Saito, T., Fujii, T., Kanatani, Y., Saijo, M., Morikawa, S., Yokote, H., Takeuchi, T. & Kuwabara, N. (2009). Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301, 1025-1033.
30. Shchelkunov, S. N., Blinov, V. M., Resenchuk, S. M., Totmenin, A. V., Olenina, L. V., Chirikova, G. B. & Sandakhchiev, L. S. (1994). Analysis of the nucleotide sequence of 53 kbp from the right terminus of the genome of variola major virus strain India-1967. Virus Res 34, 207-236.
31. Shchelkunov, S. N., Massung, R. F. & Esposito, J. J. (1995). Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Res 36, 107-118.
32. Stickl, H. & Hochstein-Mintzel, V. (1971). [Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (''MVA virus'')]. Munch Med Wochenschr 113, 1149-1153 (in German).
33. Takahashi-Nishimaki, F., Funahashi, S., Miki, K., Hashizume, S. & Sugimoto, M. (1991). Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181, 158-164.
34. Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J. C., Cox, W. I., Davis, S. W., van der Hoeven, J., Meignier, B. & Riviere, M. (1992). NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217-232.
35. Wolffe, E. J., Isaacs, S. N. & Moss, B. (1993). Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J Virol 67, 4732-4741.